Cardiovascular Health

Palliative care may help reduce symptoms and improve quality-of-life for patients with cardiovascular disease.

Perinatal depression increases the risk of cardiovascular disease in women.

Semaglutide significantly improved heart failure symptoms and quality of life through weight loss and direct effects on heart tissue.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Treatment focuses on reducing symptoms and preventing further progression.

Adopting the Planetary Health Diet may reduce overall risk of chronic disease and premature death.

Study shows that orange peel extract may reduce risk of heart disease and adverse cardiovascular events.

Research has found that increased consumption of sugar alcohols, like xylitol, may increase risk of cardiovascular events.

Study reveals vigorous physical activity correlates with lower rates of cognitive impairment in hypertensive patients.

Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.

In prior studies, higher levels of physical activity were associated with higher prevalence of coronary artery calcium.

Small steps can accumulate and have a big impact on patients’ lives

Added data from the SELECT trial helps to increase confidence in safety and efficacy of semaglutide, a glucagon-like peptide 1 medication.

Continued disparities of gender representation in cardiovascular research reveal oversights that impact adequate diagnosis and treatment of cardiovascular disease in women.

A lipoprotein (a) (Lp[a]) assay has been granted breakthrough device designation to expand identification of patients with elevated Lp(a) and genetic predispositions to cardiovascular disease.

The results showed that individuals treated with milvexian had a prolonged aPTT in a dose-dependent manner with limited effects of PT.

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.

The potential for RNAi to offer targeted and sustained control of blood pressure may represent a transformative approach in the broader landscape of cardiovascular therapeutics.

Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.

Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.

The authors emphasize that additional research addressing disparities and including race, age, and ethnicity should be conducted.

At Asembia's AXS24 Summit, a clinician discusses the pathophysiology and classification of pulmonary arterial hypertension.

Experts on the management of ASCVD discuss clinical practice patterns of high-risk patients and the common reasons for clinicians not intensifying cholesterol treatment.

A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated with maximally tolerated statin monotherapy.

Investigators found that 89% of individuals with cardiovascular disease consumed more than 1500 mg of sodium daily.

The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.

SGLT-2 inhibitors reduce cardiovascular deaths, heart failure hospitalizations, hyperkalemia, and decline of renal function in patients with HFrEF.

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.